Oral Nirmatrelvir/Ritonavir Therapy for COVID-19: The Dawn in the Dark?

Nirmatrelvir/ritonavir (Paxlovid™) is an effective and safe antiviral drug that inhibits the main protease (M(pro)), 3CL protease, of SARS-CoV-2. A reduction in COVID-19-related hospitalization or death was observed in patients treated with nirmatrelvir/ritonavir within five days of symptom onset. M...

Descripción completa

Detalles Bibliográficos
Autores principales: Hung, Yuan-Pin, Lee, Jen-Chieh, Chiu, Chun-Wei, Lee, Ching-Chi, Tsai, Pei-Jane, Hsu, I-Lin, Ko, Wen-Chien
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8868411/
https://www.ncbi.nlm.nih.gov/pubmed/35203821
http://dx.doi.org/10.3390/antibiotics11020220

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8868411/
https://www.ncbi.nlm.nih.gov/pubmed/35203821
http://dx.doi.org/10.3390/antibiotics11020220

Ejemplares similares